Microtubules are a component of the cytoskeleton. Microtubules are found in eukaryotic cells and are formed by the polymerization of a dimer of two globular proteins, alpha and beta tubulin.…
EGFR-mutated (EGFRm+) non-small cell lung cancer (NSCLC) is a major clinical problem. Tyrosine kinase inhibitors (TKIs) have precision therapeutic implications for advanced NSCLC. However, common EGFR mutations, such as EGFRL858R,…
The EGFR family of receptor tyrosine kinases (RTK) comprises four distinct receptors: the EGFR (also known as ErbB-1/HER1), ErbB-2 (neu, HER2), ErbB-3 (HER3) and ErbB-4 (HER4). These structurally related receptors…
ATR kinase is a key component of the DNA damage response pathway. Additionally, it plays a critical role in maintaining genome stability. Ceralasertib (AZD6738) is a potent inhibitor of ATR…
KRAS plays a critical role in regulating cell growth and division. KRAS mutations are common in many types of solid tumors, including lung, colon, and pancreatic cancers, and are associated…
B7-H3 (CD276) is a T cell co-stimulator and co-suppressor molecule. Specifically, B7-H3 plays an important role in tumor cell apoptosis, proliferation, adhesion, angiogenesis, invasion, migration, and escape from immune surveillance.…
EGFR (epidermal growth factor receptor) is a member of the ErbB receptor family1. Besides, EGFR is a common therapeutic strategy in epithelioma such as lung adenocarcinoma, colon cancer, head and…
Kirsten rat sarcoma (KRAS) is a member of the RAS family. KRAS is a key regulator of signaling pathways responsible for cell proliferation, differentiation, and survival. KRAS mutations are genetic…
SUV39H2 is a histone lysine-specific methyltransferase. Specifically, SUV39H2 introduced H3K9me3 to induce transcriptional inhibition. This plays a key role in heterochromatin maintenance, DNA repair, more recently, carcinogenesis. Besides, the genetic…
On December 12, 2022, FDA granted accelerated approval to Adagrasib (Krazati), for adult patients with KRAS G12C-mutated locally advanced or metastatic NSCLC. In 2021, FDA approved the selective KRASG12C mutant…